Insurance · Founded 2008 · www.nivabupa.com · BSE 544286 · NSE NIVABUPA · ISIN INE995S01015
No Notes Added Yet
Company Name: Niva Bupa Health Insurance Company Ltd.
Ticker: NIVABUPA
Country: India
Sector: Insurance
Industry: Insurance
1. Business Overview
Niva Bupa Health Insurance Company Ltd. is a specialized health insurance provider in India. The company offers a range of health insurance products, including individual, family floater, critical illness, and corporate group policies. Its core business model involves underwriting health insurance policies, collecting premiums, and managing claims. The company makes money primarily through premiums collected from policyholders, net of claims paid and operating expenses, supplemented by investment income generated from the float (funds held before claims are paid out).
2. Key Segments / Revenue Mix
Niva Bupa's primary business segments revolve around different types of health insurance policies. While specific revenue percentages are not publicly disclosed without financial reports, the main categories include:
Individual Health Insurance: Policies sold to individual customers.
Family Floater Health Insurance: Policies covering multiple family members under a single sum insured.
Group / Corporate Health Insurance: Policies provided to employer groups or organizations for their employees.
3. Industry & Positioning
The Indian health insurance industry is characterized by significant growth potential, driven by low penetration, rising healthcare costs, and increasing health awareness. It is a competitive landscape comprising public sector insurers, private general insurers, and specialized health insurers. Niva Bupa is one of the leading specialized standalone health insurers in India, known for its focus purely on health products. It positions itself on comprehensive coverage, strong customer service, and an extensive cashless hospital network, differentiating itself from general insurers who offer a wider product portfolio.
4. Competitive Advantage (Moat)
Specialization: As a standalone health insurer, Niva Bupa possesses deep expertise and focus solely on health insurance products, leading to tailored offerings and potentially better claims management.
Brand Recognition: An established brand name, benefiting from its long-standing presence and association (previously Max Bupa) and the international repute of Bupa.
Extensive Network: A wide network of cashless hospitals and healthcare providers across India, enhancing convenience for policyholders.
Customer Service & Innovation: Often cited for its customer-centric approach, product innovation, and digital initiatives to streamline policy purchase and claims.
Joint Venture Strength: The partnership with Bupa (a global healthcare leader) provides access to international best practices, operational expertise, and capital, while the Indian partner (Manipal Group) offers local market understanding and distribution reach.
5. Growth Drivers
Underpenetration: India's low health insurance penetration rates offer a substantial long-term growth runway.
Rising Healthcare Costs: Increasing medical inflation and cost of treatments compel individuals and families to seek health insurance.
Health Awareness: Growing awareness about health and wellness, significantly boosted by events like the COVID-19 pandemic, is driving demand.
Digital Adoption: Increasing digitalization makes it easier for customers to purchase policies, manage claims, and access services.
Expanding Distribution: Continued expansion into Tier 2/3 cities and leveraging digital channels will tap into new customer segments.
Government Initiatives: Schemes like Ayushman Bharat are raising overall awareness and setting benchmarks for health coverage.
6. Risks
Intense Competition: The presence of numerous public and private insurers leads to pricing pressures and challenges in market share acquisition.
High Claims Ratio: Unforeseen medical events, pandemics, and medical inflation can lead to higher-than-expected claims payouts, impacting profitability.
Regulatory Changes: Changes in IRDAI (Insurance Regulatory and Development Authority of India) regulations concerning pricing, product features, solvency norms, or distribution can impact business operations and profitability.
Economic Downturns: Reduced disposable income during economic slowdowns may affect demand for new policies or renewals.
Investment Income Volatility: Fluctuations in financial markets can impact the investment income earned on the company's float.
Data Security: The nature of the business involves handling sensitive personal and medical data, posing risks of cyber-attacks and data breaches.
7. Management & Ownership
Niva Bupa Health Insurance is a joint venture between the Manipal Group (led by Dr. Ranjan Pai) and Bupa, a leading international healthcare group based in the UK. The Manipal Group holds a 51% stake, and Bupa holds 49%. The management team typically comprises professionals with experience in the insurance and healthcare sectors, leveraging the strategic guidance and operational expertise from both joint venture partners. This structure aims to combine global best practices with strong local market understanding.
8. Outlook
Niva Bupa is well-positioned to capitalize on the significant growth potential within India's health insurance sector, driven by increasing health awareness and rising healthcare costs. Its specialization, established brand, and extensive network provide a competitive edge. However, the company operates in a highly competitive and evolving regulatory environment, necessitating efficient claims management, continuous product innovation, and robust digital integration to maintain profitability and market share. Its ability to balance aggressive growth with prudent underwriting and operational efficiency will be critical for sustained success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 950 | 1218 | 1018 | 1213 | 1136 | 1527 | 1220 | 1422 | 1454 | 1972 |
| Other Income | 126 | 154 | 191 | 187 | 159 | 99 | 153 | 170 | 164 | 143 |
| Total Income | 1076 | 1372 | 1209 | 1400 | 1295 | 1626 | 1373 | 1592 | 1618 | 2114 |
| Total Expenditure | 1071 | 1215 | 1228 | 1387 | 1282 | 1420 | 1464 | 1627 | 1705 | 1773 |
| Operating Profit | 5 | 157 | -19 | 13 | 13 | 206 | -91 | -35 | -88 | 341 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 5 | 157 | -19 | 13 | 13 | 206 | -91 | -35 | -88 | 341 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4 |
| Profit After Tax | 5 | 157 | -19 | 13 | 13 | 206 | -91 | -35 | -88 | 345 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 5 | 157 | -19 | 13 | 13 | 206 | -91 | -35 | -88 | 345 |
| Adjusted Earnings Per Share | 0 | 0.9 | -0.1 | 0.1 | 0.1 | 1.1 | -0.5 | -0.2 | -0.5 | 1.9 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 315 | 393 | 544 | 576 | 659 | 841 | 1151 | 1753 | 2663 | 3811 | 4894 | 6068 |
| Other Income | 18 | 25 | 34 | 30 | 170 | 188 | 233 | 359 | 499 | 384 | 430 | 630 |
| Total Income | 333 | 419 | 578 | 606 | 830 | 1030 | 1384 | 2112 | 3161 | 4196 | 5324 | 6697 |
| Total Expenditure | 438 | 500 | 493 | 496 | 744 | 912 | 1259 | 2066 | 2810 | 4008 | 5144 | 6569 |
| Operating Profit | -105 | -81 | 85 | 110 | 86 | 117 | 125 | 45 | 351 | 188 | 180 | 127 |
| Interest | 1 | 2 | 2 | 2 | 3 | 4 | 6 | 10 | 18 | 26 | 37 | 0 |
| Depreciation | 12 | 11 | 12 | 16 | 16 | 21 | 22 | 27 | 32 | 29 | 25 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -93 | -68 | -4 | 23 | -48 | -62 | -50 | -197 | 13 | 82 | 214 | 127 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4 |
| Profit After Tax | -93 | -68 | -4 | 23 | -48 | -62 | -50 | -197 | 13 | 82 | 214 | 131 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -93 | -68 | -4 | 23 | -48 | -62 | -50 | -197 | 13 | 82 | 214 | 131 |
| Adjusted Earnings Per Share | -1.2 | -0.8 | -0 | 0.2 | -0.5 | -0.5 | -0.4 | -1.4 | 0.1 | 0.5 | 1.2 | 0.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 28% | 41% | 42% | 32% |
| Operating Profit CAGR | -4% | 59% | 9% | 0% |
| PAT CAGR | 161% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -0% | NA% | NA% | NA% |
| ROE Average | 8% | 5% | -6% | -14% |
| ROCE Average | 8% | 5% | -5% | -14% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 170 | 209 | 233 | 256 | 262 | 346 | 577 | 508 | 831 | 2050 | 3061 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 250 | 250 | 250 | 250 |
| Other Non-Current Liabilities | 207 | 266 | 286 | 298 | 390 | 502 | 686 | 1090 | 1611 | 2228 | 2700 |
| Total Current Liabilities | 132 | 170 | 207 | 267 | 348 | 389 | 636 | 891 | 1184 | 1664 | 3749 |
| Total Liabilities | 509 | 645 | 726 | 821 | 999 | 1237 | 1899 | 2738 | 3877 | 6192 | 9760 |
| Fixed Assets | 30 | 22 | 32 | 37 | 30 | 39 | 46 | 49 | 52 | 58 | 66 |
| Other Non-Current Assets | 433 | 568 | 628 | 666 | 818 | 1070 | 1623 | 2402 | 3370 | 5459 | 8184 |
| Total Current Assets | 47 | 55 | 66 | 118 | 152 | 129 | 230 | 287 | 455 | 675 | 1510 |
| Total Assets | 509 | 645 | 726 | 821 | 999 | 1237 | 1899 | 2738 | 3877 | 6192 | 9760 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 14 | 12 | 69 | 81 | 53 | 83 | 32 | 196 | 59 | 102 | 143 |
| Cash Flow from Operating Activities | -47 | -2 | 8 | 15 | 94 | 107 | 257 | 338 | 593 | 813 | 1654 |
| Cash Flow from Investing Activities | -77 | -104 | -24 | -43 | -120 | -303 | -374 | -761 | -829 | -1882 | -2348 |
| Cash Flow from Financing Activities | 122 | 108 | 28 | 0 | 55 | 145 | 280 | 374 | 280 | 1110 | 771 |
| Net Cash Inflow / Outflow | -2 | 1 | 12 | -28 | 29 | -51 | 164 | -49 | 43 | 41 | 78 |
| Closing Cash & Cash Equivalent | 12 | 13 | 81 | 53 | 83 | 32 | 196 | 146 | 102 | 143 | 220 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1.18 | -0.76 | -0.04 | 0.25 | -0.49 | -0.55 | -0.37 | -1.4 | 0.08 | 0.48 | 1.17 |
| CEPS(Rs) | -1.18 | -0.76 | -0.04 | 0.25 | -0.49 | -0.55 | -0.37 | -1.4 | 0.08 | 0.48 | 1.17 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 2.15 | 2.32 | 2.52 | 2.76 | 2.68 | 3.07 | 4.27 | 3.6 | 5.5 | 12.06 | 16.74 |
| Core EBITDA Margin(%) | -39.01 | -27.2 | 9.44 | 13.93 | -12.81 | -8.48 | -9.36 | -17.91 | -5.54 | -5.15 | -5.1 |
| EBIT Margin(%) | -29.6 | -17.42 | -0.68 | 3.97 | -7.34 | -7.32 | -4.32 | -11.21 | 0.47 | 2.15 | 4.36 |
| Pre Tax Margin(%) | -29.6 | -17.42 | -0.68 | 3.97 | -7.34 | -7.32 | -4.32 | -11.21 | 0.47 | 2.15 | 4.36 |
| PAT Margin (%) | -29.6 | -17.42 | -0.68 | 3.97 | -7.34 | -7.32 | -4.32 | -11.21 | 0.47 | 2.15 | 4.36 |
| Cash Profit Margin (%) | -29.6 | -17.42 | -0.68 | 3.97 | -7.34 | -7.32 | -4.32 | -11.21 | 0.47 | 2.15 | 4.36 |
| ROA(%) | -59.83 | -36.17 | -1.66 | 9.34 | -18.67 | -20.23 | -10.78 | -29.5 | 1.37 | 4.85 | 7.61 |
| ROE(%) | -59.86 | -36.21 | -1.66 | 9.34 | -18.67 | -20.24 | -10.78 | -36.26 | 1.87 | 5.68 | 8.36 |
| ROCE(%) | -59.86 | -36.21 | -1.66 | 9.34 | -18.67 | -20.24 | -10.78 | -29.46 | 1.36 | 4.84 | 7.62 |
| Receivable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.75 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.66 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 2.47 | 2.25 | 1.67 | 1.56 | 1.44 | 1.32 | 1.15 | 0.77 | 0.53 | 0.47 | 2.92 |
| EV/Core EBITDA(x) | -7.41 | -10.86 | 10.68 | 8.15 | 11.1 | 9.45 | 10.56 | 29.94 | 4.01 | 9.61 | 79.33 |
| Net Sales Growth(%) | 32.64 | 24.7 | 38.46 | 5.8 | 14.52 | 27.54 | 36.83 | 52.28 | 51.94 | 43.13 | 28.42 |
| EBIT Growth(%) | 29.77 | 26.59 | 94.63 | 721.22 | -311.85 | -27.21 | 19.19 | -295.11 | 106.38 | 552.66 | 160.87 |
| PAT Growth(%) | 29.77 | 26.59 | 94.63 | 721.22 | -311.85 | -27.21 | 19.19 | -295.11 | 106.38 | 552.66 | 160.87 |
| EPS Growth(%) | 40.57 | 35.38 | 94.79 | 721.22 | -299.98 | -10.83 | 32.59 | -278.6 | 105.95 | 480.14 | 142.67 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.12 | 0.08 |
| Current Ratio(x) | 0.14 | 0.13 | 0.13 | 0.21 | 0.21 | 0.14 | 0.17 | 0.15 | 0.16 | 0.17 | 0.23 |
| Quick Ratio(x) | 0.14 | 0.13 | 0.13 | 0.21 | 0.21 | 0.14 | 0.17 | 0.15 | 0.16 | 0.17 | 0.23 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 55.98 | 55.98 | 55.43 | 55.41 | 55.36 | 55.36 |
| FII | 8.85 | 8.9 | 10.76 | 10.72 | 10.32 | 10.6 |
| DII | 9.79 | 9.67 | 15.03 | 15.27 | 16.01 | 16.46 |
| Public | 25.39 | 25.46 | 18.78 | 18.6 | 18.31 | 17.59 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 102.27 | 102.27 | 102.27 | 102.27 | 102.27 | 102.27 |
| FII | 16.17 | 16.26 | 19.86 | 19.79 | 19.06 | 19.58 |
| DII | 17.88 | 17.66 | 27.72 | 28.18 | 29.56 | 30.4 |
| Public | 46.39 | 46.51 | 34.66 | 34.33 | 33.83 | 32.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 182.7 | 182.7 | 184.51 | 184.57 | 184.72 | 184.75 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +28% | +41% | +42% | +32% |
| Operating Profit CAGR | -4% | +59% | +9% | — |
| PAT CAGR | +161% | — | — | — |
| Share Price CAGR | 0% | — | — | — |
| ROE Average | +8% | +5% | -6% | -14% |
| ROCE Average | +8% | +5% | -5% | -14% |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 55.98 | 55.98 | 55.43 | 55.41 | 55.36 | 55.36 |
| FII | 8.85 | 8.9 | 10.76 | 10.72 | 10.32 | 10.6 |
| DII | 9.79 | 9.67 | 15.03 | 15.27 | 16.01 | 16.46 |
| Public | 44.02 | 44.02 | 44.57 | 44.59 | 44.64 | 44.64 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 102.27 | 102.27 | 102.27 | 102.27 | 102.27 | 102.27 |
| FII | 16.17 | 16.26 | 19.86 | 19.79 | 19.06 | 19.58 |
| DII | 17.88 | 17.66 | 27.72 | 28.18 | 29.56 | 30.4 |
| Public | 80.43 | 80.43 | 82.24 | 82.3 | 82.45 | 82.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 182.7 | 182.7 | 184.51 | 184.57 | 184.72 | 184.75 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.